# Advancements in prostate cancer treatments > Developing situation record from CLSTR: https://clstr.news/situations/advancements-in-prostate-cancer-treatments > Updated: 2026-10-28T03:00:00.000Z. Sources: 15. Developments: 2. Recent developments in prostate cancer therapy have focused on new drug approvals and clinical trial results aimed at reducing metastasis and recurrence risks. In the United States, the FDA approved the combination of talazoparib and enzalutamide for treating metastatic hormone-sensitive prostate cancer in patients with homologous recombination repair (HRR) gene mutations. This follows the phase 3 TALAPRO-3 trial, which indicated that adding talazoparib to enzalutamide reduced the risk of radiographic progression or death by 52%. At the 2026 European Society for Medical Oncology congress, further clinical data were presented. The Phase 3 Dasl-Hicap study found that combining darolutamide, androgen deprivation therapy, and locoregional radiotherapy reduced the risk of metastasis or death by 58% in high-risk patients. Additionally, the Phase 3 PROTEUS sub-study showed that administering apalutamide with androgen deprivation therapy perioperatively reduced the risk of disease recurrence or death by 62% compared to radical prostatectomy alone. ## Timeline ### 2026-10-28: Prostate cancer treatments show significant reduction in metastasis risk Clinical trials presented at ESMO 2026 show that darolutamide and apalutamide, combined with hormone therapy, significantly reduce the risk of metastasis and death in high-risk prostate cancer patients. 11 sources. https://clstr.news/cluster/clinical-studies-show-reduced-recurrence-risk-in-high-risk-prostate-cancer ### 2026-10-26: FDA approves talazoparib and enzalutamide for metastatic prostate cancer The FDA approved talazoparib and enzalutamide for HRR-mutated metastatic hormone-sensitive prostate cancer, reducing the risk of progression or death by 52% in clinical trials. 4 sources. https://clstr.news/cluster/fda-approves-talazoparib-and-enzalutamide-for-metastatic-prostate-cancer --- Cite as: Advancements in prostate cancer treatments. CLSTR, https://clstr.news/situations/advancements-in-prostate-cancer-treatments